<DOC>
	<DOCNO>NCT01656031</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cytarabine clofarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase II trial study clofarabine give together cytarabine see well work treat patient refractory relapse acute myeloid leukemia acute lymphoblastic leukemia .</brief_summary>
	<brief_title>A Phase II Open-Label Study High-Dose Cytarabine Clofarabine Adult Patients With Refractory Relapsed Acute Myelogenous Leukemia Refractory Relapsed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate adult patient relapse refractory acute myeloid leukemia acute lymphoblastic leukemia treat high-dose cytarabine follow clofarabine . OUTLINE : This open-label phase II study . Patients stratify accord diagnosis ( acute myeloid leukemia v acute lymphoblastic leukemia Phase II : Patients receive high-dose cytarabine follow clofarabine ( dose determine phase I ) day 1-3 . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 39 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologic confirmation acute myeloid leukemia ( AML ) acute lymphoblastic leukemia ( ALL ) No M3 AML Meets 1 follow criterion : In first relapse In second relapse second complete remission ( CR ) last ≥ 3 month Refractory initial induction therapy No symptomatic CNS involvement PATIENT CHARACTERISTICS : ECOG performance status ≤ 2 Creatinine &lt; 2 mg/dL Bilirubin ≤ 2 mg/dL AST ALT ≤ 4 time upper limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 week complete study treatment Ejection fraction ≥ 45 % echocardiogram No active , uncontrolled systemic infection consider opportunistic , lifethreatening , clinically significant No psychiatric disorder would interfere give consent , study participation , followup procedures No severe concurrent disease would preclude study treatment PRIOR CONCURRENT THERAPY : At least 1 week since prior therapy recover No concurrent chemotherapy Hydroxyurea control WBC count start study treatment allow No concurrent corticosteroids unless use disease leukemia No concurrent palliative radiotherapy No concurrent growth factor ( e.g. , epoetin alfa , filgrastim [ GCSF ] , sargramostim [ GMCSF ] ) patient AML</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
</DOC>